Novel bacterial metabolite merochlorin a demonstrates in vitro activity against Multi-Drug resistant Methicillin-Resistant Staphylococcus aureus

PLoS ONE

Volumn 7, Issue 1, 2012, Pages

  Sakoulas, George ^a   Nam, Sang Jip ^b   Loesgen, Sandra ^b   Fenical, William ^a,b   Jensen, Paul R ^b   Nizet, Victor ^a   Hensler, Mary ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; DAPTOMYCIN; LINEZOLID; MEROCHLORIN A; UNCLASSIFIED DRUG; VANCOMYCIN; FUSED ALICYCLIC AROMATIC COMPOUND; SESTERTERPENE;

AGAR DILUTION; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; BROTH DILUTION; CLOSTRIDIUM DIFFICILE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG ISOLATION; DRUG PURIFICATION; DRUG SCREENING; DRUG STRUCTURE; GENE MUTATION; GRAM POSITIVE BACTERIUM; HUMAN; HUMAN CELL; IN VITRO STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MULTIDRUG RESISTANCE; NONHUMAN; PHENOTYPE; ACTINOBACTERIA; ANIMAL; AQUATIC SPECIES; CELL SURVIVAL; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECT; HELA CELL; METABOLISM; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; MOUSE; STAPHYLOCOCCUS INFECTION; TUMOR CELL LINE;

BACTERIA (MICROORGANISMS); CLOSTRIDIUM; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NEGIBACTERIA; POSIBACTERIA; STAPHYLOCOCCUS AUREUS;

ACTINOBACTERIA; ANIMALS; ANTI-BACTERIAL AGENTS; AQUATIC ORGANISMS; BENZOCYCLOHEPTENES; CELL LINE, TUMOR; CELL SURVIVAL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; GRAM-POSITIVE BACTERIA; HELA CELLS; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICE; MICROBIAL SENSITIVITY TESTS; MOLECULAR STRUCTURE; SESTERTERPENES; STAPHYLOCOCCAL INFECTIONS;

EID: 84855919642     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0029439     Document Type: Article

References (19)

1. Jarvis WR, Schlosser J, Chinn RY, Tweeten S, Jackson M, (2007) National prevalence of methicillin-resistant Staphylococcus aureus in inpatients at US health care facilities, 2006. Am J Infect Control 35: 631-637.
2. Klein E, Smith DL, Laxminarayan R, (2007) Hospitalizations and deaths caused by methicillin resistant Staphylococcus aureus, United States, 1999-2005. Emerg Infect Dis 13: 1840-1846.
3. Cosgrove S, Sakoulas G, Perencevich EN, Schwaber MJ, Karchmer AW, et al. (2003) Mortality related to methicillin-resistant Staphylococcus aureus compared to methicillin-susceptible S. aureus: a meta-analysis. Clin Infect Dis 36: 53-59.
4. Klevens RM, Morrison MA, Nadle J, Petit S, Gershman K, et al. (2007) Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA 298: 1763-1771.
5. Sakoulas G, Moellering RC, (2008) Methicillin-resistant Staphylococcus aureus (MRSA): increasing antibiotic resistance. Clin Infect Dis 46 (Suppl 5): S360-S367.
6. Tsiodras S, Gold HS, Sakoulas G, Eliopoulos GM, Wennersten C, et al. (2001) Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet 358: 207-208.
7. Sakoulas G, Gold HS, Moellering RC, Ferraro MJ, Eliopoulos GM, (2003) Introduction of ermC into a clinical linezolid- and methicillin-resistant Staphylococcus aureus does not restore linezolid susceptibility. J Antimicrob Chemother 51: 1039-1041.
8. Meka VG, Pillai SK, Sakoulas G, Wennersten C, Venkataraman L, et al. (2004) Linezolid resistance in sequential Staphylococcus aureus blood culture isolates associated with a T2500A mutation in the 23S rRNA gene and loss of a single copy of this gene. J Infect Dis 190: 311-317.
9. Sakoulas G, Eliopoulos GM, Moellering RC, Wennersten C, Venkataraman L, et al. (2002) Characterization of the accessory gene regulator (agr) locus in geographically diverse Staphylococcus aureus with reduced susceptibility in vancomycin. Antimicrob Agents Chemother 46: 1492-1502.
10. Sakoulas G, Rose W, Rybak MJ, Pillai S, Alder J, et al. (2008) Evaluation of methicillin-susceptible Staphylococcus aureus endocarditis developing nonsusceptibility to daptomycin. J Clin Microbiol 46: 220-224.
11. Yang SJ, Kreiswith BN, Sakoulas G, Yeaman MR, Xiong YQ, et al. (2009) Enhanced expression of dltABCD is associated with the development of daptomycin nonsusceptibility in a clinical endocarditis isolate of Staphylococcus aureus. J Infect Dis 200: 1916-1920.
12. Sakoulas G, Eliopoulos GM, Moellering RC, Novick RP, Venkataraman L, et al. (2003) Accessory gene regulator (agr) group II Staphylococcus aureus: is there a relationship to the development of intermediate-level glycopeptide resistance? J Infect Dis 187: 929-938.
13. Centers for Disease Control and Prevention (1997) Update: Staphylococcus aureus with reduced susceptibility to vancomycin-United States, 1997. Morbid Mortal Weekly Rep 46: 813-815.
14. Centers for Disease Control and Prevention (2002) Public Health Dispatch: Vancomycin-resistant Staphylococcus aureus-Pennsylvania Morbid Mortal Weekly Rep 51: 902.
15. Centers for Disease Control and Prevention (2002) Staphylococcus aureus resistant to vancomcyin-United States, 2002. Morbid Mortal Weekly Rep 51: 565-567.
16. Sarkera SD, Naharb L, Kumarasamyc Y, (2007) Microtitre plate-based antibacterial assay incorporating resazurin as an indicator of cell growth, and its application in the in vitro antibacterial screening of phytochemicals. Methods 42: 321-324.
17. Zurenko GE, Yagi BH, Schaadt RD, Allison JW, Kilburn KO, Glickman SE, et al. (1996) In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents. Antimicrob Agents Chemother 40: 839-45.
18. Craig WA, Gudmundsson S, (1996) Postantibiotic effect. In: Lorian V, editors. Antibiotics in laboratory medicine, 4th ed Baltimore, MD Williams and Wilkins pp. 296-329.
19. Coates T, Bax R, Coates A, (2009) Nasal decolonization of Staphylococcus aureus with mupirocin: strengths, weaknesses, and future prospects. J Antimicrob Chemother 64: 9-15.